Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates from the ENHANCE Study By admin / 09/24/2025
Real world clinical experience from ENABLE, the first Phase 4 observational study for patients with relapsing multiple sclerosis initiating ublituximab By admin / 09/24/2025
Long-Term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from 6 Years of ULTIMATE I and II Open-Label By admin / 09/24/2025
Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies By admin / 09/18/2024
Five Years of Ublituximab in Relapsing Multiple Sclerosis: Results from the Open-Label Extension of ULTIMATE I and II Studies By admin / 09/18/2024
Efficacy and Tolerability of Ublituximab after Transitioning from a Different Disease-Modifying Therapy: Updates from the ENHANCE Study By admin / 09/18/2024
Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies By admin / 10/12/2023
Evaluating the Maintenance of Efficacy and Tolerability when Transitioning from IV anti-CD20 Therapy to Ublituximab: ENHANCE Study Design, Patient Demographics and Preliminary Data By admin / 10/11/2023
Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies By admin / 10/11/2023
Functional Systems Scores and Expanded Disability Status Scale Score Evaluations in the ULTIMATE I and II Studies of Ublituximab Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis By admin / 10/26/2022
